诺和诺德
NVO49.450USD
-0.590-1.18%
收盘 10/31, 16:00（美东）报价延迟15分钟
166.35B总市值
10.28市盈率 TTM
关于 诺和诺德 公司
诺和诺德是一家专注糖尿病护理的全球医疗健康公司，同时涉足药物的发现、研发、生产与行销。公司透过「糖尿病与肥胖护理」及「生物制药」两大业务运作。前者产品组合含胰岛素、GLP-1 受体激动剂（Ozempic、Wegovy、Rybelsus 等） 、胰高血糖素等蛋白质类疗法、蛋白质投递系统与注射针头，以及口服降糖药；后者聚焦血友病护理、生长激素补充及激素替代治疗。另有 Saxenda 专门针对临床肥胖症。主要品牌包含 NovoLog/NovoRapid、NovoLog Mix/NovoMix、Prandin/NovoNorm、NovoSeven、Norditropin、Vagifem 等。公司药品销往逾一百八十个国家，全球商业体系由北美与国际运营两大区域组成，透过临床研究、制造网络与市场渠道将疗法带给患者。
诺和诺德简介
公司代码NVO
公司名称Novo Nordisk A/S
上市日期May 17, 1974
CEOMr. Maziar Mike Doustdar
员工数量76302
证券类型Ordinary Share
年结日May 17
公司地址Novo Alle 1
城市BAGSVAERD
上市交易所The Toronto Stock Exchange
国家Denmark
邮编2880
电话4544448888
网址https://www.novonordisk.com/
公司代码NVO
上市日期May 17, 1974
CEOMr. Maziar Mike Doustdar
诺和诺德公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Emil Kongshoj Larsen
Mr. Emil Kongshoj Larsen
Executive Vice President - International Operations
Executive Vice President - International Operations
--
--
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Ms. Thilde Hummel Bogebjerg
Ms. Thilde Hummel Bogebjerg
Executive Vice President - Quality, IT & Environmental Affairs
Executive Vice President - Quality, IT & Environmental Affairs
--
--
Mr. Helge Lund
Mr. Helge Lund
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Thomas Rantzau
Mr. Thomas Rantzau
Director, Employee Representative
Director, Employee Representative
--
--
Ms. Tania Sabroe
Ms. Tania Sabroe
Executive Vice President - People, Organisation & Corporate Affairs
Executive Vice President - People, Organisation & Corporate Affairs
--
--
Dr. Martin Holst Lange
Dr. Martin Holst Lange
Executive Vice President, Chief Scientific Officer, Research & Development
Executive Vice President, Chief Scientific Officer, Research & Development
--
--
Mr. Andreas Fibig
Mr. Andreas Fibig
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Emil Kongshoj Larsen
Mr. Emil Kongshoj Larsen
Executive Vice President - International Operations
Executive Vice President - International Operations
--
--
Mr. Jacob Martin Wiborg Rode
Mr. Jacob Martin Wiborg Rode
Head of Investor Relations
Head of Investor Relations
--
--
Ms. Thilde Hummel Bogebjerg
Ms. Thilde Hummel Bogebjerg
Executive Vice President - Quality, IT & Environmental Affairs
Executive Vice President - Quality, IT & Environmental Affairs
--
--
Mr. Helge Lund
Mr. Helge Lund
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. David Moore
Mr. David Moore
Executive Vice President - US Operations and Business Development
Executive Vice President - US Operations and Business Development
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Total GLP-1
5.83B
49.92%
Obesity (Wegovy®)
2.97B
25.41%
Fast-acting insulin
689.86M
5.91%
Long-acting insulin
678.47M
5.81%
Rare blood disorders
470.23M
4.03%
其他
1.04B
8.92%
地区USD
名称
营收
占比
USA
6.53B
55.90%
Canada
2.50B
21.40%
Emerging Markets
1.15B
9.82%
APAC
852.83M
7.31%
Region China
651.28M
5.58%
业务
地区
业务USD
名称
营收
占比
Total GLP-1
5.83B
49.92%
Obesity (Wegovy®)
2.97B
25.41%
Fast-acting insulin
689.86M
5.91%
Long-acting insulin
678.47M
5.81%
Rare blood disorders
470.23M
4.03%
其他
1.04B
8.92%
股东统计
更新时间: 22 小时前
更新时间: 22 小时前
持股股东
股东类型
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
0.38%
Loomis, Sayles & Company, L.P.
0.37%
Capital International Investors
0.35%
Fisher Investments
0.33%
Fayez Sarofim & Co.
0.31%
其他
98.26%
持股股东
持股股东
占比
Fidelity Management & Research Company LLC
0.38%
Loomis, Sayles & Company, L.P.
0.37%
Capital International Investors
0.35%
Fisher Investments
0.33%
Fayez Sarofim & Co.
0.31%
其他
98.26%
股东类型
持股股东
占比
Investment Advisor
4.69%
Investment Advisor/Hedge Fund
2.73%
Research Firm
0.89%
Hedge Fund
0.40%
Pension Fund
0.32%
Insurance Company
0.19%
Bank and Trust
0.16%
Family Office
0.02%
Family Office
0.02%
其他
90.58%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
2753
315.93M
9.39%
-25.52M
2025Q2
2754
330.35M
9.82%
-31.19M
2025Q1
2769
336.08M
9.99%
-21.71M
2024Q4
2676
348.53M
10.35%
+330.19K
2024Q3
2529
339.29M
10.15%
-6.04M
2024Q2
2456
341.24M
10.21%
+6.87M
2024Q1
2291
330.25M
9.75%
+10.89M
2023Q4
2037
314.57M
9.30%
+1.47M
2023Q3
1826
307.14M
8.91%
+4.22M
2023Q2
1692
293.83M
8.50%
+768.69K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Fidelity Management & Research Company LLC
12.93M
0.38%
+3.95M
+44.01%
Jun 30, 2025
Loomis, Sayles & Company, L.P.
12.58M
0.37%
+187.79K
+1.52%
Jun 30, 2025
Capital International Investors
11.62M
0.35%
+2.11M
+22.18%
Jun 30, 2025
Fisher Investments
11.00M
0.33%
-870.32K
-7.33%
Jun 30, 2025
Fayez Sarofim & Co.
10.50M
0.31%
-708.84K
-6.32%
Jun 30, 2025
Folketrygdfondet
10.09M
0.3%
+572.63K
+6.01%
Jun 30, 2025
Managed Account Advisors LLC
8.81M
0.26%
+195.59K
+2.27%
Jun 30, 2025
ClearBridge Investments, LLC
8.22M
0.24%
+1.59M
+23.95%
Jun 30, 2025
Everett Harris & Co.
6.39M
0.19%
-13.84K
-0.22%
Jun 30, 2025
Parametric Portfolio Associates LLC
6.23M
0.19%
+587.70K
+10.42%
Jun 30, 2025
查看更多
持股ETF
更新时间: 10月6日 周一
更新时间: 10月6日 周一
机构名称
占比
Roundhill GLP-1 & Weight Loss ETF
19.58%
Amplify Weight Loss Drug & Treatment ETF
9.11%
VanEck Pharmaceutical ETF
6.13%
The Opal International Dividend Income ETF
4.19%
TrueShares Low Volatility Equity Income ETF
2.57%
First Trust WCM International Equity ETF
2.28%
Invesco International Dividend Achievers ETF
1.16%
SP Funds S&P World (ex-US) ETF
1.13%
Amplify International Enhanced Dividend Income ETF
0.79%
ActivePassive International Equity ETF
0.79%
查看更多
Roundhill GLP-1 & Weight Loss ETF
占比19.58%
Amplify Weight Loss Drug & Treatment ETF
占比9.11%
VanEck Pharmaceutical ETF
占比6.13%
The Opal International Dividend Income ETF
占比4.19%
TrueShares Low Volatility Equity Income ETF
占比2.57%
First Trust WCM International Equity ETF
占比2.28%
Invesco International Dividend Achievers ETF
占比1.16%
SP Funds S&P World (ex-US) ETF
占比1.13%
Amplify International Enhanced Dividend Income ETF
占比0.79%
ActivePassive International Equity ETF
占比0.79%
分红派息
近5年累计派现
21.09B
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Aug 06, 2024
NVO.NB Final Cash Dividend of gross USD 0.516902 paid on Aug 26, 2024 going ex on Aug 16, 2024
Aug 16, 2024
Aug 26, 2024
Aug 16, 2024
Jan 31, 2024
NVO.NB Interim Cash Dividend of gross USD 0.929335 paid on Apr 02, 2024 going ex on Mar 22, 2024
Mar 25, 2024
Apr 02, 2024
Mar 22, 2024
Aug 10, 2023
NVO.NB Final Cash Dividend of gross USD 0.876339 paid on Aug 29, 2023 going ex on Aug 18, 2023
Aug 21, 2023
Aug 29, 2023
Aug 18, 2023
Feb 02, 2023
NVO.NB Interim Cash Dividend of gross USD 1.180581 paid on Apr 04, 2023 going ex on Mar 24, 2023
Mar 27, 2023
Apr 04, 2023
Mar 24, 2023
Aug 04, 2022
NVO.NB Final Cash Dividend of gross USD 0.577745 paid on Aug 23, 2022 going ex on Aug 12, 2022
Aug 15, 2022
Aug 23, 2022
Aug 12, 2022
Mar 02, 2022
NVO.NB Interim Cash Dividend of gross USD 1.022424 paid on Apr 05, 2022 going ex on Mar 25, 2022
Mar 28, 2022
Apr 05, 2022
Mar 25, 2022
Aug 05, 2021
NVO.NB Final Cash Dividend of gross USD 0.550289 paid on Aug 25, 2021 going ex on Aug 16, 2021
Aug 17, 2021
Aug 25, 2021
Aug 16, 2021
Feb 22, 2021
NVO.NB Interim Cash Dividend of gross USD 0.922122 paid on Apr 07, 2021 going ex on Mar 26, 2021
Mar 29, 2021
Apr 07, 2021
Mar 26, 2021
Aug 06, 2020
NVO.NB Final Cash Dividend of gross USD 0.517777 paid on Aug 25, 2020 going ex on Aug 14, 2020
Aug 17, 2020
Aug 25, 2020
Aug 14, 2020
Feb 06, 2020
NVO.NB Interim Cash Dividend of gross USD 0.782605 paid on Apr 07, 2020 going ex on Mar 27, 2020
Mar 30, 2020
Apr 07, 2020
Mar 27, 2020
拆合股
公告日期
类型
比率
Aug 14, 2023
Split
1→2
公告日期
类型
比率
Aug 14, 2023
Split
1→2
